||5R01CA067338-04 Interpret this number
||Risk Factors and Biomarkers for in Situ Breast Cancer
Heightened utilization of mammography has resulted in dramatic increases
in the occurrence of breast carcinoma in situ, yet the public health
significance of these lesions remains controversial. We propose a multi-
center population-based case-control study to evaluate risk factors and
biomarkers of breast carcinoma in situ. We will examine the influence of
established risk factors for invasive breast carcinoma on BCIS as well
as newly identified risk factors, such as alcohol consumption,
postmenopausal hormone use, and physical activity. We will evaluate risk
factors for BCIS and its major subtypes, lobular carcinoma in situ
(LCIS), ductal carcinoma in sine (DCIS), and the aggressive DCIS subtype
(comedo-type DCIS). Thus, we will distinguish etiologic factors,
including potentially modifiable exposures, that may be related to
specific subtypes of biologic significance. In addition, we will be able
to compare BCIS risk factors with those identified in our current case-
control study of invasive breast cancer. Our unique approach will allow
an investigation of risk factors related to tumors of apparently
incremental malignant significance. This study will utilize our existing
and highly successful consortium of population-based, case-control
studies of breast cancer. In the proposed study, we will interview over
a 36 month period, 1,570 women with breast carcinoma in situ identified
from the WI, MA, and NH state cancer registries. For comparison, about
2,200 population-based controls will be randomly selected from drivers'
license lists and from Medicare beneficiary files in each state. This
approach will permit the evaluation of two control groups: women with a
recent mammographic history, and general population controls. Consenting
subjects will participate in a telephone interview. The proposed study,
which includes sufficient numbers of BCIS subtypes of disparate malignant
potential, provides a unique opportunity to evaluate biomarkers in
relation to early disease development. Thus, we propose to evaluate the
relationship between BCIS (and its subtypes) to p53 mutations, HER-2/neu
amplifications, and NAT2 genotype. These biomarkers are related to
invasive breast cancer; our design will allow us to evaluate the extent
to which these markers are related to LCIS, DCIS, and the comedo-type
DCIS. In addition, we will evaluate the relation between these biomarkers
and exposures; this approach may elucidate risk factors involved in early
disease development. The findings of this study may have important
implications for breast cancer prevention and intervention. In addition,
this study will establish the foundation for follow-up studies.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.